

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

October 18, 2023

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on October 18,2023

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Wednesday, October 18, 2023, inter-alia:

- 1. considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023. The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. Execution of Power Delivery Agreement with Sunpound Solar Private Limited (Sunpound) a Special Purpose Vehicle (SPV), for supply of electricity by Power Producer to the Company, by setting up a group captive solar power project in Maharashtra. In this regard the Company has agreed to invest an amount upto Rs. 1.10 Crores to subscribe equity shares, upto 26% of share capital of Sunpound in proportion to the contracted capacity by captive consumers. The necessary further details shall be disclosed to the Stock Exchanges upon execution of the Share Subscription and Share Holder's Agreement.

Details required as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1 /P/CI R/2023/123 dated July 13, 2023 are enclosed as Annexure - A.

The meeting commenced at 03:00 p.m. and concluded at 06.00 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited RAJESH RAMESH Digitally signed by RAJESH RAMESH SHIRAMBEKAR

Date: 2023.10.18 18:06:42 SHIRAMBEKAR /-

Rajesh Shirambekar Head – Legal & Company Secretary





RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

Annexure - A

(Disclosure under Regulation 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements)

Regul	Regulations, 2015						
1	Name of the target entity, details in brief such as size, turnover etc.;	Sunpound Solar Private Limited ("Sunpound"), is promoted as a special purpose vehicle, solely to undertake in the business of construction, operation and maintenance of the Captive Generating Plant and to supply, on captive basis, the power generated from the Captive Generating Plant to the Company.					
		The Company proposes to make investment of amount up to Rs. 1.10 Crores (Rupees one crores and ten lakhs only) in one or more tranches, in accordance with the terms and Share Subscription and Shareholders Agreement ("SSSHA")					
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Sunpound is not a related party of the Company, and hence acquisition of shares of Sunpound does not fall within the category of related party transaction. Promoter/ promoter group/ group companies do not have any interest in Sunpound.					
3	Industry to which the entity being acquired belongs;	Generation of Solar Power.					
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	In line with the statutory requirements to avail power / electricity for captive usage and energy cost saving, the Company is required to subscribe to the equity share capital of Sunpound.					
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable					
6	Indicative time period for completion of the acquisition;	One year					
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash Consideration					
8	Cost of acquisition and/or the price at which the shares are acquired;	Up to Rs. 1.10 Crores (Rupees one crores and ten lakhs only), in one or more tranches					
9	Percentage of shareholding / control acquired and / or number of shares acquired;	Up to 26% of the equity share capital of Sunpound in proportion to the Contracted Capacity, in accordance with the terms and conditions specified under the SSSHA.					
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Sunpound Solar Private Limited ("Sunpound", is a company incorporated on March 23, 2022. The registered office of Sunpound is situated in Mumbai. Sunpound is inter alia, engaged in Generation of Solar Power. Turnover: Nil.					



Chartered Accountants

12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai - 400 028, India

Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors RPG Life Sciences Limited

- We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended September 30, 2023 and year to date from April 01, 2023, to September 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

BC

For S R B C & CO LLP Chartered Accountants

ICAI Firm registration number: 324982E/E300003

per Aruna Kumaraswamy

Partner

Membership No.: 219350

UDIN: 23219350 BC X WIKT

Place: Mumbai

Date: October 18, 2023



RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2023

		Ouarter ended Six months ended			hs ended	(Rs. in Lakhs) Year ended	
	Particulars	30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
	a a tectuary	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	15,358	14,778	13,479	30.136	26,372	51,281
2	Other Income	183	181	123	364	245	480
3	Total Income (1+2)	15,541	14,959	13,602	30,500	26,617	51,761
4	Expenses						
	(a) Cost of Materials Consumed	3.730	3,047	2,218	6,777	4,344	8,612
	(b) Purchases of Stock-in-Trade	1,311	1,666	2.628	2,977	4,640	9,205
	(c) Changes in Inventories of Finished Goods, Work-						
	in-Progress and Stock-in-Trade	(567)	305	(309)	(262)	(93)	(730)
	(d) Employee Benefits Expense	3,359	3.279	2,792	6,638	5,500	11,706
	(c) Finance Costs	10	7	8	17	19	31
	(f) Depreciation and Amortisation Expense	423	421	387	844	770	1.550
	(g) Other Expenses	3,796	3,257	3.177	7,053	6,224	12,219
	Total Expenses	12,062	11,982	10,901	24,044	21,404	42,593
5	Profit before tax (3-4)	3,479	2,977	2,701	6,456	5,213	9,168
6	Income tax expenses						
	a. Current Tax	967	792	716	1,759	1,374	2,435
	b. Deferred Tax	(74)	(25)	(12)	(99)	21	(31)
7	Profit for the period (5-6)	2,586	2,210	1,997	4,796	3,818	6,764
8	Other Comprehensive Income						
	(i) Items that will not be reclassified to Profit or Loss	3	2	(9)	5	(18)	9
	(ii) Income tax relating to items that will not be						
	reclassified to Profit or Loss	(1)	(1)	3	(2)	5	(2)
	Other Comprehensive Income Net of Tax	2	1	(6)	3	(13)	7
9	Total Comprehensive Income for the period (7+8)	2,588	2,211	1,991	4,799	3,805	6,771
10	Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
11	Other Equity						29,437
12	Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
	(a) Basic (in Rs.)	15.64	13.36	12.08	29.00	23.09	40.90
	(b) Diluted (in Rs.)	15.64	13.36	12.08	29.00	23.09	40.90

SIGNED FOR IDENTIFICATION
BY
SRBC&COLLP
MUMBAI

MUMBAI 400 030.

B.M. D8 W



RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road

Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

Unaudited Balance Sheet as at September 30, 2023

(Rs. in Lakhs)

		(Rs. in Lakhs)		
Particulars	As at September 30, 2023	As at March 31, 2023		
	(Unaudited)	(Audited)		
ASSETS				
Non-current assets				
Property, plant and equipment (Including Right of use assets)	9,786	10,127		
Capital work-in-progress	4,191	1,503		
Other intangible assets	1,961	2,299		
Intangible assets under development	1,051	1,041		
Financial assets				
i. Loans	18	18		
ii. Other financial assets	44	44		
Current Tax asset (Nct)	193	173		
Other non-current assets	833	325		
Total non-current assets	18,077	15,530		
Current assets				
Inventories	10,057	9,505		
Financial assets				
i. Investments	7,894	5,843		
ii. Loans	2	2		
iii. Trade receivables	6,007	3,743		
iv. Cash and cash equivalents	2,232	2,482		
v. Bank balances other than (iv) above	69	3,222		
vi. Other financial assets	113	135		
Other current assets	1,663	1,473		
Total current assets	28,037	26,405		
Total assets	46,114	41,935		
EQUITY AND LIABILITIES	10,111	11,755		
Equity				
Equity share capital	1,323	1,323		
Other equity	32,251	29,437		
Total equity	33,574	30,760		
Liabilities	33,374	50,700		
Non-current liabilities				
Financial liabilities				
i. Other financial liabilities	303	302		
Provisions	406	398		
Deferred tax liabilities (Net)	96			
Total non-current liabilities	805	197 89 7		
Current liabilities	003	097		
Financial liabilities				
i. Borrowings				
ii. Trade payables	-	1		
(a) total outstanding dues of micro enterprises and small enterprises				
Control Parish Medicardo Control	344	482		
(b) total outstanding dues of creditors other than micro	10.00000			
enterprises and small enterprises	6,556	5,987		
iii. Other financial liabilities	2,557	2,002		
Provisions	1,161	1,186		
Current tax liabilities (Net)	601	-		
Other current liabilities	516	620		
Total current liabilities	11,735	10,278		
Total liabilities	12,540	11,175		
Total equity and liabilities	46,114	41,935		

SIGNED FOR IDENTIFICATION
BY
SRBC&COLLP
MUMBAI

MUMBAI 400 030.

B.M. DE V



RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375

Fax: +91-22-24970127

Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

Unaudited statement of cash flows for the six months ended September 30, 2023

(Rs. in Lakhs)

		(Rs. in Lakhs)			
P	Particulars	For the period ended September 30, 2023	For the period ended September 30, 2022		
		Unaudited	Unaudited		
A C	Cash Flow from operating activities				
P	Profit before income tax	6,456	5,213		
A	Adjustments for				
A	Add/(Less):				
	Depreciation and amortisation expenses	844	770		
F	inance costs	17	19		
L	oss on disposal of property, plant and equipment	2	2		
U	Inrealised exchange rate difference	(16)	(49)		
P	Provision for Doubtful Debts and Advances (Net)	255	21		
I	nterest received	(92)	(141)		
C	Gain on sale of investments	(105)	(8)		
N	Net fair value gain on financial assets mandatorily measured at fair value				
	hrough profit or loss	(151)	-		
		7,210	5,825		
v	Vorking capital adjustments:				
	Increase) in trade receivables	(2.507)	(1,989)		
	Increase) in financial assets - Loans	(2,503)			
1.0	Decrease / (Increase) in other financial assets		(9)		
	Increase) / Decrease in other current assets	22	(22)		
100	Increase) / Decrease in other current assets	(190)	436		
100		(552)	(181)		
	ncrease in trade payables	431	982		
	ncrease / (Decrease) in other financial liabilities	301	(200)		
100	Decrease) in provisions	(13)	(163)		
	Decrease) in other current liabilities	(104)	(33)		
	Cash generated from operations	4,602	4,646		
	ncome taxes paid	(1,178)	(1,097)		
115	Net cash inflow from operating activities	3,424	3,549		
B	Cash flow from investing activities:				
A	Acquisition of property, plant and equipment and Intangible assets	(3,136)	(989)		
P	roceeds from sale of property, plant and equipment and Intangible assets	6			
N	Movement in Other bank balances (Net)	3,153	(10)		
	nvestment in Mutual Funds	(1,900)	(1,650)		
11	nterest received	92	141		
N	let gain on sale of investments	105			
N	let cash (outflow) from investing activities	(1,680)	(2,508)		
c c	Cash flow from financing activities				
200	roceeds from/ (Repayment of) long term borrowings	(1)	(5)		
	Proceeds from/ (Repayment of) Short-term Borrowings		19		
	nterest paid	(8)	(5)		
1000	Repayment of principal portion of lease liability	(0)	(65)		
1000	nterest paid on lease liability		(4)		
	Dividend paid	(1,985)	(1,588)		
	let cash (outflow) from financing activities	(1,994)	(1,648		
N	let (decrease)/increase in cash and cash equivalents	(250)	(607)		
	Add: Cash and cash equivalents at the beginning of the financial period	2,482	5,694		
1 8	Cash and cash equivalents at the end of the period	2,232	5,087		

Notes

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee and have been approved by the Board
 of Directors at their respective meetings held on October 18, 2023.
- 2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- 3. Previous period's figures have been regrouped/reclassified wherever necessary.

SIGNED FOR IDENTIFICATION
BY
SRBC&COLLP
MUMBAI



For RPG Life Sciences Limited

Yugal Sikii Managing Director Mumbai, October 18, 2023